Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun;93(3):323-331.
doi: 10.1590/abd1806-4841.20186972.

Tuberous sclerosis complex: review based on new diagnostic criteria

Larissa Karine Leite Portocarrero  1 , Klícia Novais Quental  1 , Luciana Paula Samorano  1 , Zilda Najjar Prado de Oliveira  1 , Maria Cecília da Matta Rivitti-Machado  1
Affiliations
Review

Tuberous sclerosis complex: review based on new diagnostic criteria

Larissa Karine Leite Portocarrero et al. An Bras Dermatol. 2018 Jun.

Abstract

Tuberous sclerosis complex is a multisystemic, autosomal dominant genetic disorder with complete penetrance, that can evolve with hamartomas in multiple organs, such as skin, central nervous system, kidney and lung. Due to the wide phenotypic variability, the disease is often not recognized. Tuberous sclerosis complex affects one in 10,000 newborns and most patients are diagnosed during the first 15 months of life. The diagnostic criteria for tuberous sclerosis were reviewed in 2012, at the second International Tuberous Sclerosis Complex Consensus Conference. The diagnosis is based on genetic criteria, by the identification of inactivating pathogenic mutation of tumor suppressor genes TSC1 and TSC2, and clinical criteria, including cutaneous, renal, pulmonary, cardiac and neurological manifestations. The treatment of tuberous sclerosis complex consists, mainly, in management of the symptoms caused by hamartomas and in prevention of organ failure. Multidisciplinary approach is recommended, in order to obtain better clinical outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflict of interests: None.

Figures

Figure 1
Figure 1
A - Fibrous cephalic plaque; B - Facial angiofibromas; C - Intraoral fibroma; D - Dental B enamel pits
Figure 2
Figure 2
A - “Ash-leaf” hypopigmented macules; B - Shagreen patch; C - Periungual fibroma (Koenen tumor)
See this image and copyright information in PMC

References

    1. Rodrigues DA, Gomes CM, Costa IMC. Tuberous sclerosis complex. An Bras Dermatol. 2012;87:184–196. - PubMed
    1. Hinton RB, Prakash A, Romp RL, Krueger DA, Knilans TK, International Tuberous Sclerosis Consensus Group Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group. J Am Heart Assoc. 2014;3:e001493. - PMC - PubMed
    1. Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013 Oct;49(4):243–254. - PMC - PubMed
    1. Sadowski K, Kotulska K, Schwartz RA, Józwiak S. Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review. J Eur Acad Dermatol Venereol. 2016;30:586–594. - PubMed
    1. DiMario Jr FJ, Sahin M, Ebrahimi-Fakhari D. Tuberous SclerosisComplex. Pediatr Clin North Am. 2015;62:633–648. - PubMed